Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of Ischemic stroke

American Journal of Cardiovascular Drugs

Volumn 3, Issue 2, 2003, Pages 87-94

  Lapchak, Paul A ^a,b   Araujo, Dalia M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 (4 AMIDINOBENZAMIDO)PROPIONAMIDO] 2 (4 ETHYLBENZENESULFONAMIDO)PROPIONIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; ARGATROBAN; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; IMMUNOGLOBULIN F(AB) FRAGMENT; LOTRAFIBAN; ME 3277; ORBOFIBAN; PLACEBO; RETEPLASE; SDZ GPI 562; SDZ GPI 652; SIBRAFIBAN; STREPTOKINASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; TP 201; UNCLASSIFIED DRUG; XEMILOFIBAN;

ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CAROTID ARTERY SURGERY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG TOLERABILITY; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; META ANALYSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANIMALS; BRAIN ISCHEMIA; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STROKE; THROMBOLYTIC THERAPY;

EID: 0038318995     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303020-00002     Document Type: Article

References (60)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333 (24): 1581-7
2. Lapchak PA, Araujo DM. Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs 2001; 15 (11): 819-29
3. Lapchak PA. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep 2002; 2 (1): 38-43
4. Cannon CP. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol (2000) 23 Suppl 6: VI-14-7
5. Catella-Lawson F. Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Neurology 2001; 57 (5): S5-7
6. Ferguson JJ, Vaisman D. Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction. Expert Opin Investig Drugs 2001; 10 (11): 1965-76
7. Futterman LG, Lemberg L. Harnessing the platelet. Am J Crit Care 1997; 6 (5): 406-14
8. Thomas S. Platelet membrane glycoproteins in haemostasis. Clin Lab 2002; 48 (5-6): 247-62
9. Zhang ZG, Zhang L, Tsang W, et al. Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res 2001; 912 (2): 181-94
10. Lapchak PA, Araujo DM, Song D, et al. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM- 20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke. Stroke 2002; 33 (1): 147-52
11. Leclerc JR. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Crit Care Med 2002; 30 (5 Suppl.): S332-40
12. Casserly IP, Topol EJ. Glycoprotein IIb/IIIa antagonists-from bench to practice. Cell Mol Life Sci 2002; 59 (3): 478-500
13. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP Iib/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 2000; 36 (2): 381-6
14. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344 (25): 1888-94
15. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo- controlled trials of percutaneous coronary revascularization. Am J Med 2002; 113 (1): 1-6
16. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344 (25): 1895-903
17. Tepe G, Schott U, Erley CM, et al. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis. AJR Am J Roentgenol (1999) 172(5):1343-6
18. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98 (8): 734-41
19. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340 (21): 1623-9
20. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357 (9272): 1905-14
21. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo- controlled, et al. The Abciximab in Ischemic Stroke Investigators. Stroke 2000; 31 (3): 601-9
22. Adams H, Barnathan E, Bogousslavsky J, et al. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2003. In press
23. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/lIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo- controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997; 95 (4): 846-54
24. Dyke CM, Bhatia D, Lorenz TJ, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg 2000; 70 (3): 866-71; discussion 871-2
25. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 1999; 99 (22): 2892-900
26. Mahaffey KW, Harrington RA, Simoons ML, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation 1999; 99 (18): 2371-7
27. Mckay RG, Boden WE. Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials. Curr Opin Cardiol 2001; 16 (6): 364-9
28. Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999; 354 (9192): 1757-62
29. Januzzi JL Jr, Snapinn SM, Dibattiste PM, et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 2002; 105 (20): 2361-6
30. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96 (5): 1445-53
31. Cannon CP, Weintraub WS, Demopoulos LA, et al. Invasive versus conservative strategies in unstable angina and non-Q- wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am J Cardiol 1998; 82 (6): 731-6
32. Topol EJ, Easton JD, Amarenco P, et al. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. Am Heart J 2000; 139 (6): 927-33
33. Sorelle R. SmithKline Beecham halts tests of lotrafiban, an oral glycoprotein IIb/IIIa inhibitor. Circulation 2001; 103 (1): E9001-2
34. Easton JD. Future perspectives for optimizing oral antiplatelet therapy. Cerebrovasc Dis 2001; 11 Suppl. 2: 23-8
35. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99 (21): 2720-32
36. Gilchrist IC, Nickolaus MJ, Momplaisir T. Same-day transradial outpatient stenting with a 6-hr course of glycoprotein IIb/IIIa receptor blockade: a feasibility study. Catheter Cardiovasc Interv 2002; 56 (1): 10-3
37. Qureshi AI, Ali Z, Suri MF, et al. Open-label phase I clinical study to assess the safety of intravenous eptifibatide in patients undergoing internal carotid artery angioplasty and stent placement. Neurosurgery 2001; 48 (5): 998-1004; discussion 1004-5
38. Mould D, Chapelsky M, Aluri J, et al. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients. Clin Pharmacol Ther 2001; 69 (4): 210-22
39. Hofmann R, Kerschner K, Steinwender C, et al. Abciximab bolus injection does not reduce cerebral ischemic complications of elective carotid artery stenting: a randomized study. Stroke 2002; 33 (3): 725-7
40. Qureshi AI, Suri MF, Khan J, et al. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience. Neurosurgery 2000; 46 (6): 1316-24; discussion 1324-5
41. Qureshi AI, Saad M, Zaidat OO, et al. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke 2002; 33 (7): 1916-9
42. Dietrich WD, Dewanjee S, Prado R, et al. Transient platelet accumulation in the rat brain after common carotid artery thrombosis: an 111In-labeled platelet study. Stroke 1993; 24 (10): 1534-40
43. Choudhri TF, Hoh BL, Zerwes HG, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest 1998; 102 (7): 1301-10
44. Choudhri TF, Hoh BL, Prestigiacomo CJ, et al. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. J Exp Med 1999; 190 (1): 91-9
45. Abumiya T, Fitridge R, Mazur C, et al. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 2000; 31 (6): 1402-09; discussion 1409-10
46. Kawano KI, Fujishima K, Ikeda Y, et al. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery. J Cereb Blood Flow Metab 2000; 20 (6): 988-97
47. Shuaib A, Yang Y, Nakada MT, et al. Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy. J Cereb Blood Flow Metab 2002; 22 (2): 215-22
48. Huang J, Rebello SS, Faul JD, et al. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition. Pharmacology 1999; 58 (5): 252-64
49. Huang J, Rebello SS, Rosenberg LA, et al. Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model. Eur J Pharmacol 1999; 366 (2-3): 203-13
50. Sassoli PM, Emmell EL, Tam SH, et al. 7E3 F(ab')2, an effective antagonist of rat alphaIIbbeta3 and alphavbeta3, blocks in vivo thrombus formation and in vitro angiogenesis. Thromb Haemost 2001; 85 (5): 896-902
51. Horisawa S, Kaneko M, Sakurama T. SM-20302, a nonpeptide GPIIb/IIIa receptor antagonist, exhibits a wide therapeutic window in a newly developed hemorrhage model in mice. Thromb Haemost 1999; 92 (6): 1743-8
52. Rebello SS, Huang J, Shiu WJ, et al. Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. J Cardiovasc Pharmacol 1998; 32 (3): 485-94
53. Lapchak PA, Araujo DM, Song D, et al. Neuroprotective effects of the spin trap agent disodium-[tert- butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 2002; 33 (5): 1411-5
54. Lee KY, Heo JH, Lee SI, et al. Rescue treatment with abciximab in acute ischemic stroke. Neurology 2001; 56 (11): 1585-7
55. Eckert B, Koch C, Thomalla G, et al. Acute basilar artery occlusion treated with combined intravenous Abciximab and intra-arterial tissue plasminogen activator: report of 3 cases. Stroke 2002; 33 (5): 1424-7
56. Junghans U, Seitz RJ, Aulich A, et al. Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis 2001; 12 (4): 308-12
57. Junghans U, Seitz RJ, Ritzl A, et al. Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban. Neurology 2002; 58 (3): 474-6
58. Kwon OK, Lee KJ, Han MH, et al. Intraarterially administered abciximab as an adjuvant thrombolytic therapy: report of three cases. AJNR Am J Neuroradiol 2002; 23 (3): 447-51
59. Lamonte MP, Brown PM, Evans DM. A randomized, placebo-controlled, three treatment arm study to determine the safety and efficacy of argatroban injection in patients with acute ischemic stroke (ARGIS-I). Abstract CTP351. Stroke 2002, 33
60. Trivedi SM, Shani J, Hollander G. Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro). J Invasive Cardiol 2002; 14 (7): 423-5